How Will the Market React to Catalent Inc (CTLT) Stock Getting a Bullish Rating

Overall market sentiment has been high on Catalent Inc (CTLT) stock lately. CTLT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Catalent Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTLT!

See Full CTLT Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CTLT Stock Today?

Catalent Inc (CTLT) stock is down -0.6% while the S&P 500 is higher by 0.29% as of 2:51 PM on Wednesday, Nov 22. CTLT is down -$0.24 from the previous closing price of $39.84 on volume of 476,912 shares. Over the past year the S&P 500 has gained 15.22% while CTLT is down -5.47%. CTLT lost -$5.23 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Catalent Inc click here.

More About Catalent Inc

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. Click Here to get the full Stock Report for Catalent Inc stock.